An unclear offer is a reason to stop and ask.

Missing prescriptions and research labels

As of September 26, 2026, a valid prescription was required under federal law before prescription medicine could be dispensed.

At that date, the FDA warned against research-labelled tirzepatide offered to people with instructions for human use.

The agency described those products as having unknown quality and potential for harm.

Words saying “research use only” cannot replace a clinician checking your health before treatment.

Claims that blur the product

As of September 26, 2026, FDA guidance called it misleading to describe a compound as approved or as the same as an approved medicine.

It also objected to calling a compounded product a generic version of an approved drug.

FDA registration did not prove that a product was approved at that date. A National Drug Code, often shown as NDC followed by numbers on a label or website, did not prove approval either.

Ask for the medicine’s full name, who made it, and the basis for the claim.

Keep a copy of the wording so you can compare the answer with it.

A pharmacy name that cannot be checked

By September 26, 2026, fraudulent labels for tirzepatide had been found by the FDA; they named pharmacies that did not exist.

The FDA’s consumer checklist also flags services that lack a clinician to answer questions after medicine arrives.

Ask for the pharmacy name before a payment commitment, then check its state record.

Ask who handles an unclear label, a damaged parcel, or a medicine that does not match the order.

A bargain needs the other checks too.

The FDA flags unusually low prices as a concern alongside other problems; a low price alone does not prove an offer is wrong.

Compare the product, the full terms, and the care you would get.

If the answers remain unclear, you can seek another way to discuss care with a clinician.